Research Signal – Source date 2025-02-01
Penile cancer is rare, and prospective studies that could compare treatment approaches are scarce. For people with high-risk disease, that leaves difficult decisions where guidelines offer recommendations but specialist practice may differ. A survey published on February 1, 2025, describes some of those differences among specialists at high-volume European centers.
The findings are a snapshot of clinicians’ reported preferences. They do not tell patients which option is more effective, but they show why two specialist teams may approach a complex case differently.
Treatment choices varied across several parts of care
Thirty-nine specialists from high-volume centers in 13 European countries answered a cross-sectional survey. They were asked about treatment before or after primary treatment, choices of systemic drug regimens, use of immunotherapy, and whether next-generation sequencing was integrated into care.
The respondents reported variation in the use of therapy around primary treatment, as well as in systemic regimen preferences and immunotherapy use. These are different decision points: treatment timing concerns whether additional therapy is used in relation to the main treatment, while systemic regimens and immunotherapy concern the kinds of drug treatment specialists may consider.
These responses show where preferences differed, but they cannot identify which approach produced better patient outcomes.
Tumor sequencing was not widely integrated
Next-generation sequencing examines tumor-related molecular information that may help inform treatment planning. The survey identified limited integration of this tool among respondents. The survey does not establish why its integration into care was limited.
The finding does not show that sequencing changed care or improved outcomes for any patient. It identifies a reported practice pattern, while leaving open how the tool might contribute to individual decisions.
A small survey cannot rank treatments
The results came from 39 self-reporting specialists at selected high-volume centers, across 13 countries, at one point in time. The sample is small, and clinicians’ answers may not capture every detail of actual care. The survey also cannot establish how common these practices are among all European clinicians or centers.
Because it was cross-sectional and descriptive, it cannot determine whether the reported differences led to better or worse outcomes. The study therefore helps characterize decision-making uncertainty; it does not resolve which treatment choices should be preferred.
What more consistent care could mean for patients
Stronger comparative evidence and collaboration among specialist centers could help teams make more consistently justified choices for people with high-risk penile cancer. That benefit depends on future research establishing which approaches actually improve outcomes, so that recommendations can rest on evidence rather than preference alone.
Key Sources
- Primary source: Complex Decision Making for Individual Patients With Penile Cancer: Benchmarking Divergent Practices in European High-Volume Reference Centers: Results From eUROGEN Survey.
DOI or Journal Page · Peer-Reviewed Paper · 2025-02-01
Keep exploring